Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications

European Archives of Oto-Rhino-Laryngology

Volumn 271, Issue 2, 2014, Pages 211-223

  Hunt, Jennifer L ^a   Barnes, Leon ^b   Lewis Jr , James S ^c   Mahfouz, Magdy E ^d   Slootweg, Pieter J ^e   Thompson, Lester D R ^f   Cardesa, Antonio ^g   Devaney, Kenneth O ^h   Gnepp, Douglas R ⁱ   Westra, William H ^j   Rodrigo, Juan P ^k,l   Woolgar, Julia A ^m   Rinaldo, Alessandra ⁿ   Triantafyllou, Asterios ^m   Takes, Robert P ^e   Ferlito, Alfio ⁿ  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Kafrelsheikh University   (Egypt)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f WOODLAND HILLS MEDICAL CENTER   (United States)

^g HOSPITAL CLÍNIC   (Spain)

^h Department of Pathology Allegiance Health ^*  (United States)

ⁱ BROWN UNIVERSITY   (United States)

^j DEPARTMENT OF PATHOLOGY   (United States)

^k HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^l DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^m UNIVERSITY OF LIVERPOOL   (United Kingdom)

ⁿ UNIVERSITY OF UDINE   (Italy)

more..

Author keywords

Carcinogenesis; Diagnostic test; Gene expression; Head and neck squamous cell carcinoma; Molecular biology; Oncogenes; Targeted therapy; Tumor suppressor genes

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC SUBUNIT ALPHA; PROTEIN; PROTEIN CCND 1; PROTEIN P53; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER RESISTANCE; EPSTEIN BARR VIRUS; GENE EXPRESSION PROFILING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LYMPHOEPITHELIOMA; MOLECULAR DIAGNOSIS; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; UNDIFFERENTIATED CARCINOMA; VIRUS DETECTION; VIRUS ETIOLOGY; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CYCLIN D1; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; GENES, P16; GENES, P53; GENES, RAS; HEAD AND NECK NEOPLASMS; HUMANS; PAPILLOMAVIRUS INFECTIONS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTORS, NOTCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84899049430     PISSN: 09374477     EISSN: 14344726     Source Type: Journal    
DOI: 10.1007/s00405-013-2400-9     Document Type: Review

References (156)

1. Thompson MP, Kurzrock R (2004) Epstein-Barr virus and cancer. Clin Cancer Res 10(3):803-821 (Pubitemid 38198878)
2. Chan AT (2010) Nasopharyngeal carcinoma. Ann Oncol 21(Suppl 7):vii308-vii312
3. Tao Q, Chan AT (2007) Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 9(12):1-24 (Pubitemid 47398642)
4. Cao SM, Simons MJ, Qian CN (2011) The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer 30(2):114-119
5. Chan KC, Lo YM (2002) Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol 12(6):489-496 (Pubitemid 35370761)
6. Lo YM (2001) Prognostic implication of pretreatment plasma/serum concentration of Epstein-Barr virus DNA in nasopharyngeal carcinoma. Biomed Pharmacother 55(7):362-365
7. Wei WI, Sham JS (2005) Nasopharyngeal carcinoma. Lancet 365(9476):2041-2054 (Pubitemid 40812341)
8. Brennan B (2006) Nasopharyngeal carcinoma. Orphanet J Rare Dis 1:23
9. Resta L, Ricco R, Santangelo A (1983) Morphologic and classificatory considerations about 140 cases of carcinoma of the nasopharynx. Tumori 69(4):313-321
10. Döhnert G (1971) Lymphoepithelioma Schmincke-Regaud. Virchows Arch A Pathol Pathol Anat 352(3):279-284
11. Singhi AD, Stelow EB, Mills SE, Westra WH (2010) Lymphoepithelial-like carcinoma of the oropharynx: a morphologic variant of HPV-related head and neck carcinoma. Am J Surg Pathol 34(6):800-805
12. Carpenter DH, El-Mofty SK, Lewis JS Jr (2011) Undifferentiated carcinoma of the oropharynx: a human papillomavirus-associated tumor with a favorable prognosis. Mod Pathol 24(10):1306-1312
13. Maxwell JH, Kumar B, Feng FY, McHugh JB, Cordell KG, Eisbruch A et al. (2010) HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. Head Neck 32(5):562-567
14. Li X, Fasano R, Wang E, Yao KT, Marincola FM (2009) HLA associations with nasopharyngeal carcinoma. Curr Mol Med 9(6):751-765
15. Yoshizaki T, Ito M, Murono S, Wakisaka N, Kondo S, Endo K (2012) Current understanding and management of nasopharyngeal carcinoma. Auris Nasus Larynx 39(2):137-144
16. Iwakiri D, Takada K (2010) Role of EBERs in the pathogenesis of EBV infection. Adv Cancer Res 107:119-136
17. Gulley ML, Tang W (2008) Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn 10(4):279-292 (Pubitemid 352022708)
18. Dahlstrom KR, Adler-Storthz K, Etzel CJ, Liu Z, Dillon L, El-Naggar AK et al. (2003) Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: a matched pair analysis. Clin Cancer Res 9(7):2620-2626 (Pubitemid 36842105)
19. El-Mofty SK, Lu DW (2003) Prevalence of human papillomavirus type 16 DNA in squamous cell carcinoma of the palatine tonsil, and not the oral cavity, in young patients: a distinct clinicopathologic and molecular disease entity. Am J Surg Pathol 27(11):1463-1470 (Pubitemid 37315200)
20. Marur S, D'Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11(8):781-789
21. Snow AN, Laudadio J (2010) Human papillomavirus detection in head and neck squamous cell carcinomas. Adv Anat Pathol 17(6):394-403
22. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S et al. (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100(6):407-420 (Pubitemid 351480511)
23. Westra TA, Rozenbaum MH, Rogoza RM, Nijman HW, Daemen T, Postma MJ et al. (2011) Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J Infect Dis 204(3):377-384
24. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H et al. (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100(4):261-269 (Pubitemid 351480538)
25. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM et al. (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356(19):1944-1956 (Pubitemid 46740304)
26. Ukpo OC, Pritchett CV, Lewis JE, Weaver AL, Smith DI, Moore EJ (2009) Human papillomavirus-associated oropharyngeal squamous cell carcinomas: primary tumor burden and survival in surgical patients. Ann Otol Rhinol Laryngol 118(5):368-373
27. Thavaraj S, Stokes A, Guerra E, Bible J, Halligan E, Long A et al. (2011) Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice. J Clin Pathol 64(4):308-312
28. Sugiyama M, Bhawal UK, Kawamura M, Ishioka Y, Shigeishi H, Higashikawa K et al. (2007) Human papillomavirus-16 in oral squamous cell carcinoma: clinical correlates and 5-year survival. Br J Oral Maxillofac Surg 45(2):116-122 (Pubitemid 46131998)
29. Goldenberg D, Begum S, Westra WH, Khan Z, Sciubba J, Pai SI et al. (2008) Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon. Head Neck 30(7):898-903 (Pubitemid 352008950)
30. Loyo M, Johnson JT, Westra WH, Chiosea SI, Gourin CG (2011) Management of the "violated neck" in the era of chemoradiation. Laryngoscope 121(11):2349-2358
31. Harwick RD (1991) Cervical metastases from an occult primary site. Semin Surg Oncol 7(1):2-8
32. Westra WH (2012) The morphologic profile of HPV-related head and neck squamous carcinoma: implications for diagnosis, prognosis, and clinical management. Head Neck Pathol 6(Suppl 1):S48-S54
33. Mendelsohn AH, Lai CK, Shintaku IP, Elashoff DA, Dubinett SM, Abemayor E et al. (2010) Histopathologic findings of HPV and p16 positive HNSCC. Laryngoscope 120(9):1788-1794
34. Begum S, Westra WH (2008) Basaloid squamous cell carcinoma of the head and neck is a mixed variant that can be further resolved by HPV status. Am J Surg Pathol 32(7):1044-1050
35. Friedrich RE, Sperber C, Jakel T, Roser K, Loning T (2010) Basaloid lesions of oral squamous epithelial cells and their association with HPV infection and P16 expression. Anticancer Res 30(5):1605-1612
36. Thariat J, Badoual C, Faure C, Butori C, Marcy PY, Righini CA (2010) Basaloid squamous cell carcinoma of the head and neck: role of HPV and implication in treatment and prognosis. J Clin Pathol 63(10):857-866
37. Weiss D, Koopmann M, Rudack C (2010) Prevalence and impact on clinicopathological characteristics of human papillomavirus-16 DNA in cervical lymph node metastases of head and neck squamous cell carcinoma. Head Neck 33(6):856-862
38. de Roda Husman AM, Snijders PJ, Stel HV, van den Brule AJ, Meijer CJ, Walboomers JM (1995) Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br J Cancer 72(2):412-417
39. Chan PK, Chan DP, To KF, Yu MY, Cheung JL, Cheng AF (2001) Evaluation of extraction methods from paraffin wax embedded tissues for PCR amplification of human and viral DNA. J Clin Pathol 54(5):401-403 (Pubitemid 32458142)
40. Westra WH (2012) Detection of human papillomavirus in clinical samples. Otolaryngol Clin North Am 45(4):765-777
41. Singhi AD, Westra WH (2010) Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 116(9):2166-2173
42. Gao G, Chernock RD, Gay HA, Thorstad WL, Zhang TR, Wang H et al. (2012) A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis. Int J Cancer 132(4):882-890
43. Jordan RC, Lingen MW, Perez-Ordonez B, He X, Pickard R, Koluder M et al. (2012) Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 36(7):945-954
44. Gao G, Chernock RD, Gay HA, Thorstad WL, Zhang TR, Wang H et al. (2013) A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis. Int J Cancer 132(4):882-890
45. Schache AG, Liloglou T, Risk JM, Filia A, Jones TM, Sheard J et al. (2011) Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res 17(19):6262-6271
46. Bishop JA, Maleki Z, Valsamakis A, Ogawa T, Chang X, Pai SI et al. (2012) Application of the hybrid capture 2 assay to squamous cell carcinomas of the head and neck: a convenient liquid-phase approach for the reliable determination of human papillomavirus status. Cancer Cytopathol 120(1):18-25
47. Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH (2003) Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9(17):6469-6475 (Pubitemid 38031835)
48. Begum S, Gillison ML, Nicol TL, Westra WH (2007) Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 13(4):1186-1191 (Pubitemid 46424059)
49. Ukpo OC, Flanagan JJ, Ma XJ, Luo Y, Thorstad WL, Lewis JS Jr (2011) High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol 35(9):1343-1350
50. Bishop JA, Ma XJ, Wang H, Luo Y, Illei PB, Begum S et al. (2012) Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am J Surg Pathol 36(12):1874-1882
51. El-Naggar AK, Westra WH (2012) p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck 34(4):459-461
52. Lau HY, Brar S, Klimowicz AC, Petrillo SK, Hao D, Brockton NT et al. (2010) Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy. Head Neck 33(2):251-256
53. Fischer CA, Kampmann M, Zlobec I, Green E, Tornillo L, Lugli A et al. (2010) p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters. Ann Oncol 21(10):1961-1966
54. Deschoolmeester V, Van Marck V, Baay M, Weyn C, Vermeulen P, Van Marck E et al. (2010) Detection of HPV and the role of p16INK4A overexpression as a surrogate marker for the presence of functional HPV oncoprotein E7 in colorectal cancer. BMC Cancer 10:117
55. Chernock RD, Wang X, Gao G, Lewis JS Jr, Zhang Q, Thorstad WL et al. (2012) Detection and significance of human papillomavirus, CDKN2A(p16) and CDKN1A(p21) expression in squamous cell carcinoma of the larynx. Mod Pathol 26(2):223-231
56. Lewis JS Jr, Chernock RD, Ma XJ, Flanagan JJ, Luo Y, Gao G et al. (2012) Partial p16 staining in oropharyngeal squamous cell carcinoma: extent and pattern correlate with human papillomavirus RNA status. Mod Pathol 25(9):1212-1220
57. Ma C, Lewis J Jr (2012) Small biopsy specimens reliably indicate p16 expression status of oropharyngeal squamous cell carcinoma. Head Neck Pathol 6(2):208-215
58. Lewis JS Jr, Thorstad WL, Chernock RD, Haughey BH, Yip JH, Zhang Q et al. (2010) p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 34(8):1088-1096
59. Sahu N, Grandis JR (2011) New advances in molecular approaches to head and neck squamous cell carcinoma. Anticancer Drugs 22(7):656-664
60. Smilek P, Neuwirthova J, Jarkovsky J, Dusek L, Rottenberg J, Kostrica R et al. (2012) Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas. Neoplasma 59(5):508-515
61. Chau NG, Perez-Ordonez B, Zhang K, Pham NA, Ho J, Zhang T et al. (2011) The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol 3:11
62. Ciardiello F, Tortora G (2003) Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39(10):1348-1354 (Pubitemid 36773776)
63. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52(7):893-901 (Pubitemid 38857154)
64. Herbst R, Shin D (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94(5):1593-1611 (Pubitemid 34212655)
65. Kim ES, Khuri FR, Herbst RS (2001) Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 13(6):506-513 (Pubitemid 33027904)
66. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R (2010) Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol 17(3):37-48
67. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786-792 (Pubitemid 40271173)
68. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64(24):8919-8923 (Pubitemid 39665498)
69. Hama T, Yuza Y, Suda T, Saito Y, Norizoe C, Kato T et al. (2012) Functional mutation analysis of EGFR family genes and corresponding lymph node metastases in head and neck squamous cell carcinoma. Clin Exp Metastasis 29(1):19-25
70. Szabo B, Nelhubel GA, Karpati A, Kenessey I, Jori B, Szekely C et al. (2011) Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncol 47(6):487-496
71. Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW et al. (2011) Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci USA 108(47):19024-19029
72. Lee JW, Soung YH, Kim SY, Nam HK, Park WS, Nam SW et al. (2005) Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 11(8):2879-2882
73. Sheikh Ali MA, Gunduz M, Nagatsuka H, Gunduz E, Cengiz B, Fukushima K et al. (2008) Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 99(8):1589-1594
74. López F, Llorente JL, Oviedo CM, Vivanco B, Alvarez Marcos CÁ, García-Inclán C et al. (2011) Gene amplification and protein overexpression of EGFR and ERBB2 in sinonasal squamous cell carcinoma. Cancer 118(7):1818-1826
75. Licitra L, Mesia R, Rivera F, Remenar E, Hitt R, Erfan J et al. (2011) Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 22(5):1078-1087
76. Rodrigo JP, Ramos S, Lazo PS, Alvarez I, Suárez C (1996) Amplification of ERBB oncogenes in squamous cell carcinomas of the head and neck. Eur J Cancer 32A(11):2004-2010 (Pubitemid 26361698)
77. Modjtahedi H, Khelwatty SA, Kirk RS, Seddon AM, Essapen S, Del Vecchio CA et al. (2012) Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. Br J Cancer 106(5):883-888
78. Langer CJ (2012) Exploring biomarkers in head and neck cancer. Cancer 118(16):3882-3892
79. Sheu JJ, Hua CH, Wan L, Lin YJ, Lai MT, Tseng HC et al. (2009) Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res 69(6):2568-2576
80. Tsui IF, Poh CF, Garnis C, Rosin MP, Zhang L, Lam WL (2009) Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias. Int J Cancer 125(9):2219-2228
81. Feng Z, Guo W, Zhang C, Xu Q, Zhang P, Sun J et al. (2011) CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. PLoS ONE 6(10):e26399
82. Kaminagakura E, Werneck da Cunha I, Soares FA, Nishimoto IN, Kowalski LP (2011) CCND1 amplification and protein overexpression in oral squamous cell carcinoma of young patients. Head Neck 33(10):1413-1419
83. Nadal A, Jares P, Pinyol M, Conde L, Romeu C, Fernandez PL et al. (2007) Association of CDK4 and CCND1 mRNA overexpression in laryngeal squamous cell carcinomas occurs without CDK4 amplification. Virchows Arch 450(2):161-167 (Pubitemid 46295221)
84. Ragin CC, Taioli E, Weissfeld JL, White JS, Rossie KM, Modugno F et al. (2006) 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br J Cancer 95(10):1432-1438 (Pubitemid 44760098)
85. Rodrigo JP, García LA, Ramos S, Lazo PS, Suárez C (2000) EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res 6(8):3177-3182 (Pubitemid 30637745)
86. Rodrigo JP, Garcia-Carracedo D, Garcia LA, Menendez S, Allonca E, Gonzalez MV et al. (2009) Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas. J Pathol 217(4):516-523
87. Murray S, Karavasilis V, Bobos M, Razis E, Papadopoulos S, Christodoulou C et al. (2012) Molecular predictors of response to tyrosine kinase inhibitors in patients with non-small-cell lung cancer. J Exp Clin Cancer Res 31(1):77
88. Siddiqui AD, Piperdi B (2010) KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol 17(4):1168-1176
89. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A et al. (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333(6046):1157-1160
90. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ et al. (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333(6046):1154-1157
91. Suda T, Hama T, Kondo S, Yuza Y, Yosikawa M, Urashima M et al. (2012) Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma. BMC Cancer 12(1):416
92. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T et al. (2012) The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22(11):2109-2119
93. Weber A, Langhanki L, Sommerer F, Markwarth A, Wittekind C, Tannapfel A (2003) Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 22(30):4757-4759 (Pubitemid 36976451)
94. Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS et al. (2005) Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 114(2):242-248 (Pubitemid 40194293)
95. Loyo M, Li RJ, Bettegowda C, Pickering CR, Frederick MJ, Myers JN et al. (2013) Lessons learned from next-generation sequencing in head and neck cancer. Head Neck 35(3):454-463
96. Cohen Y, Goldenberg-Cohen N, Shalmon B, Shani T, Oren S, Amariglio N et al. (2011) Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma. Oral Oncol 47(10):946-950
97. Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N (2008) Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol 32(1):101-111 (Pubitemid 351176067)
98. Pal I, Mandal M (2012) PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin 33(12):1441-1458
99. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS et al. (2011) PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10(3):558-565
100. Bouali S, Chretien AS, Ramacci C, Rouyer M, Becuwe P, Merlin JL (2009) PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Oncol Rep 21(3):731-735
101. Suda K, Mizuuchi H, Maehara Y, Mitsudomi T (2012) Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer Metastasis Rev 31(3-4):807-814
102. Allory Y, Culine S, de la Taille A (2011) Kidney cancer pathology in the new context of targeted therapy. Pathobiology 78(2):90-98
103. Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP et al. (2010) Molecular diagnosis and therapy of kidney cancer. Ann Rev Med 61:329-343
104. Canadas I, Rojo F, Arumi-Uria M, Rovira A, Albanell J, Arriola E (2010) C-MET as a new therapeutic target for the development of novel anticancer drugs. Clin Transl Oncol 12(4):253-260
105. Belalcazar A, Azana D, Perez CA, Raez LE, Santos ES (2012) Targeting the Met pathway in lung cancer. Expert Rev Anticancer Ther 12(4):519-528
106. Cheng L, Alexander RE, Maclennan GT, Cummings OW, Montironi R, Lopez-Beltran A et al. (2012) Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 25(3):347-369
107. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M et al. (2009) The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69(7):3021-3031
108. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD et al. (2000) Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19(12):1547-1555 (Pubitemid 30175676)
109. Muller D, Millon R, Eber M, Methlin G, Abecassis J (1995) Alteration of the C-met oncogene locus in human head and neck-carcinoma. Oncol Rep 2(5):847-850
110. Ghadjar P, Blank-Liss W, Simcock M, Hegyi I, Beer KT, Moch H et al. (2009) MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. Clin Exp Metastasis 26(7):809-815
111. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT et al. (2009) HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 15(11):3740-3750
112. Lim YC, Han JH, Kang HJ, Kim YS, Lee BH, Choi EC et al. (2012) Overexpression of c-Met promotes invasion and metastasis of small oral tongue carcinoma. Oral Oncol 48(11):1114-1119
113. Lo Muzio L, Farina A, Rubini C, Coccia E, Capogreco M, Colella G et al. (2006) Effect of c-Met expression on survival in head and neck squamous cell carcinoma. Tumour Biol 27(3):115-121
114. Seiwert T, Sarantopoulos J, Kallender H, McCallum S, Keer HN, Blumenschein G Jr (2012) Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs [Epub ahead of print]
115. Bauman JE, Michel LS, Chung CH (2012) New promising molecular targets in head and neck squamous cell carcinoma. Curr Opin Oncol 24(3):235-242
116. Mehra R, Serebriiskii IG, Dunbrack RL Jr, Robinson MK, Burtness B, Golemis EA (2011) Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resist Updat 14(6):260-279
117. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68(4):820-823
118. Knudson AG Jr (1976) Genetics and the etiology of childhood cancer. Pediatr Res 10(5):513-517
119. Nadal A, Cardesa A (2003) Molecular biology of laryngeal squamous cell carcinoma. Virchows Arch 442(1):1-7 (Pubitemid 36216353)
120. Mitra S, Banerjee S, Misra C, Singh RK, Roy A, Sengupta A et al. (2007) Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population. J Clin Pathol 60(9):1040-1047 (Pubitemid 47441939)
121. Gold KA, Kim ES (2009) Role of molecular markers and gene profiling in head and neck cancers. Curr Opin Oncol 21(3):206-211
122. Shah NG, Trivedi TI, Tankshali RA, Goswami JV, Jetly DH, Shukla SN et al. (2009) Prognostic significance of molecular markers in oral squamous cell carcinoma: a multivariate analysis. Head Neck 31(12):1544-1556
123. Acin S, Li Z, Mejia O, Roop DR, El-Naggar AK, Caulin C (2011) Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J Pathol 225(4):479-489
124. Tabor MP, Brakenhoff RH, van Houten VM, Kummer JA, Snel MH, Snijders PJ et al. (2001) Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res 7(6):1523-1532 (Pubitemid 32708615)
125. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9-22
126. Graveland AP, Golusinski PJ, Buijze M, Douma R, Sons N, Kuik DJ et al. (2006) Loss of heterozygosity at 9p and p53 immunopositivity in surgical margins predict local relapse in head and neck squamous cell carcinoma. Int J Cancer 128(8):1852-1859
127. Braakhuis BJ, Snijders PJ, Keune WJ, Meijer CJ, Ruijter-Schippers HJ, Leemans CR et al. (2004) Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 96(13):998-1006 (Pubitemid 39162642)
128. Bolt J, Vo QN, Kim WJ, McWhorter AJ, Thomson J, Hagensee ME et al. (2005) The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms. Oral Oncol 41(10):1013-1020 (Pubitemid 41434067)
129. Nathan CO, Amirghahri N, Rice C, Abreo FW, Shi R, Stucker FJ (2002) Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients. Laryngoscope 112(12):2129-2140 (Pubitemid 35417033)
130. Lindenbergh-van der Plas M, Brakenhoff RH, Kuik DJ, Buijze M, Bloemena E, Snijders PJ et al. (2011) Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res 17(11):3733-3741
131. Smith BD, Haffty BG (1999) Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Radiat Oncol Investig 7(3):125-144 (Pubitemid 29310095)
132. Perrone F, Suardi S, Pastore E, Casieri P, Orsenigo M, Caramuta S et al. (2006) Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 12(22):6643-6651 (Pubitemid 44876832)
133. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM et al. (2012) TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 18(1):290-300
134. Geurts TW, van Velthuysen ML, Broekman F, van Huysduynen TH, van den Brekel MW, van Zandwijk N et al. (2009) Differential diagnosis of pulmonary carcinoma following head and neck cancer by genetic analysis. Clin Cancer Res 15(3):980-985
135. Tang M, Pires Y, Schultz M, Duarte I, Gallegos M, Wistuba II (2003) Microsatellite analysis of synchronous and metachronous tumors: a tool for double primary tumor and metastasis assessment. Diagn Mol Pathol 12(3):151-159 (Pubitemid 37040602)
136. van Houten VM, Leemans CR, Kummer JA, Dijkstra J, Kuik DJ, van den Brekel MW et al. (2004) Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res 10(11):3614-3620 (Pubitemid 38697594)
137. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ (2004) Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res 10(11):3607-3613 (Pubitemid 38697593)
138. van Houten VM, Tabor MP, van den Brekel MW, Kummer JA, Denkers F, Dijkstra J et al. (2002) Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J Pathol 198(4):476-486 (Pubitemid 35447001)
139. Egloff AM, Grandis JR (2012) Molecular pathways: context-dependent approaches to notch targeting as cancer therapy. Clin Cancer Res 18(19):5188-5195
140. Mahfouz ME, Rodrigo JP, Takes RP, Elsheikh MN, Rinaldo A, Brakenhoff RH et al. (2010) Current potential and limitations of molecular diagnostic methods in head and neck cancer. Eur Arch Otorhinolaryngol 267(6):851-860
141. Ziober AF, D'Alessandro L, Ziober BL (2010) Is gene expression profiling of head and neck cancers ready for the clinic? Biomark Med 4(4):571-580
142. Lallemant B, Evrard A, Chambon G, Sabra O, Kacha S, Lallemant JG et al. (2010) Gene expression profiling in head and neck squamous cell carcinoma: clinical perspectives. Head Neck 32(12):1712-1719
143. Mendez E, Lohavanichbutr P, Fan W, Houck JR, Rue TC, Doody DR et al. (2011) Can a metastatic gene expression profile outperform tumor size as a predictor of occult lymph node metastasis in oral cancer patients? Clin Cancer Res 17(8):2466-2473
144. Stokes A, Joutsa J, Ala-Aho R, Pitchers M, Pennington CJ, Martin C et al. (2010) Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. Clin Cancer Res 16(7):2022-2035
145. Chen C, Méndez E, Houck J, Fan W, Lohavanichbutr P, Doody D et al. (2008) Gene expression profiling identifies genes predictive of oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 17(8):2152-2162
146. Braakhuis BJ, Senft A, de Bree R, de Vries J, Ylstra B, Cloos J et al. (2006) Expression profiling and prediction of distant metastases in head and neck squamous cell carcinoma. J Clin Pathol 59(12):1254-1260 (Pubitemid 46048328)
147. van Hooff SR, Leusink FK, Roepman P, Baatenburg de Jong RJ, Speel EJ, van den Brekel MW et al. (2012) Validation of a gene expression signature for assessment of lymph node metastasis in oral squamous cell carcinoma. J Clin Oncol 30(33):4104-4110
148. Roepman P, Wessels LF, Kettelarij N, Kemmeren P, Miles AJ, Lijnzaad P et al. (2005) An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 37(2):182-186
149. Leusink FK, van Es RJ, de Bree R, Baatenburg DE, Jong RJ, Holstege FC et al. (2012) Novel diagnostic modalities for the clinically node negative neck in head and neck cancer: expression profiling and sentinel lymph node biopsy. Lancet Oncol 13(12):e554-e561
150. Braakhuis B, Graveland A, Dijk F, Ylstra B, van Wieringen W, Leemans C et al. (2012) Expression signature in peripheral blood cells for molecular diagnosis of head and neck squamous cell carcinoma. Oral Dis [Epub ahead of print]
151. Graveland AP, Braakhuis BJ, Eerenstein SE, de Bree R, Bloemena E, de Maaker M et al. (2012) Molecular diagnosis of minimal residual disease in head and neck cancer patients. Cell Oncol 35(5):367-375
152. Ferris RL, Stefanika P, Xi L, Gooding W, Seethala RR, Godfrey TE (2012) Rapid molecular detection of metastatic head and neck squamous cell carcinoma as an intraoperative adjunct to sentinel lymph node biopsy. Laryngoscope 122(5):1020-1030
153. Gao G, Gay HA, Chernock RD, Zhang TR, Luo J, Thorstad WL et al. (2012) A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma. Cancer 119(1):72-80
154. Wald AI, Hoskins EE, Wells SI, Ferris RL, Khan SA (2011) Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. Head Neck 33(4):504-512
155. Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, McClean MD et al. (2009) A let-7 microRNA-binding site polymorphism in the KRAS 3′ UTR is associated with reduced survival in oral cancers. Carcinogenesis 30(6):1003-1007
156. Nohata N, Sone Y, Hanazawa T, Fuse M, Kikkawa N, Yoshino H et al. (2011) miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget 2(1-2):29-42